A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE015 (POL) · Dr. Ito
consented 2022-08-22
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-01-03 (study day 121); relationship: not assessed
mild
assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-02-06 (study day 520); relationship: N
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-04-04 (study day 578); relationship: not assessed
Data queries
No data queries.